SERVICES
Based on years of research and trials at major medical institutions, Rebion has harnessed the breakthrough Neural Performance Scanning (NPS) to precisely measure signal patterns that return from the brain, instantly determining if faulty signal processing is present. NPS portable point-of-care devices provide previously unavailable information for fast and impactful triage, making early disease detection, intervention and customized treatment more accessible.
INNOVATIVE TECHNOLOGY
What is NPS?
Using proprietary retinal scanning to quantify bilateral fixation and saccadic movement, NPS measures the neurophysiologic mechanism of the optic nerve/brain continuum, instantly identifying impairments.
Based on years of research and development at leading medical institutions, Rebion developed Blinq®, an FDA-cleared portable vision scanning device designed to detect micro-strabismus and amblyopia rather than relying solely on the identification of associated risk factors.
Blinq performs a 3-second Neural Performance Scan of the fovea to assess binocular fixation and identify misalignment as small as 1 degree, providing an objective Pass/Refer result to support early referral and further evaluation when needed.
Leveraging NPS to measure monocular and binocular foveal fixation impairments, Rebion’s Traq™ device uses Neural Performance Scanning (NPS) to support clinical research focused on visual tracking, with the goal of translating these insights into future clinical tools. Traq is currently investigational and not available for sale in the United States.
Blinq’s Evidence & Impact
Backed by peer-reviewed clinical studies and years of research at leading medical institutions, Blinq® offers an evidence-based approach to early vision screening. Unlike traditional screening tools that primarily identify risk factors, Blinq directly assesses binocular fixation to screen for amblyopia and strabismus. In a 2021 peer-reviewed study conducted at Kaiser Permanente, the technology demonstrated 100% sensitivity and 85% overall specificity, with specificity reaching 91% among children exhibiting excellent cooperation during screening.* By supporting the early identification of children who may require further evaluation, Blinq helps healthcare providers and community screening programs make informed referral decisions and expand access to early vision care.
*Source: Shah SS, et al. “Validation of the Pediatric Vision Scanner in a normal preschool population.” Journal of AAPOS (2021). https://doi.org/10.1016/j.jaapos.2021.03.010
Who we serve
Rebion announces new CEO
Mark Maire has been tapped to lead Rebion into the future.
National Institues of Health
NIH-funded study shows screening device accurately detects amblyopia (lazy eye).
Newswire
Newly Published Clinical Trial Shows Unprecedented Accuracy of Rebion's Blinq® Vision Scanner in Pediatric Vision Screening.
